INSP - Vivos Therapeutics: First Take After The Broad Market Sell-Off
- Vivos Therapeutics, Inc. markets a jaw repositioning device that has the potential to cure patients’ mild-to-moderate obstructive sleep apnea.
- Despite an active 2021 that saw its mmRNA oral appliance cleared as a Level II device – prompting gains in insurance coverage (including Medicare) – its stock is down 60%.
- With a clearly more appealing alternative to CPAP machines and less invasive than surgery, Vivos and its oral appliances merited further investigation.
- A full investment analysis follows in the paragraphs below.
For further details see:
Vivos Therapeutics: First Take After The Broad Market Sell-Off